Rexahn Pharmaceuticals (RNN) 0.76 $RNN
Metastatic Pancreatic Cancer - Pipeline Review, H2 2014
M2 - Wed Oct 08, 4:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hnpdbv/metastatic) has announced the addition of the "Metastatic Pancreatic Cancer - Pipeline Review, H2 2014" report to their offering. This, Metastatic Pancreatic Cancer - Pipeline Review, H2 2014', provides an overview of the Metastatic Pancreatic Cancer's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Metastatic Pancreatic Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Pancreatic Cancer and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned: - F. Hoffmann-La Roche - AstraZeneca - Eli Lilly and Company - GlaxoSmithKline - Gilead Sciences - Merck & Co - FibroGen - Novartis AG - Pfizer Inc. - Silence Therapeutics plc - Celgene Corporation - Bayer AG - Incyte Corporation - Halozyme Therapeutics, Inc. - Momenta Pharmaceuticals, Inc. - Immunomedics, Inc. - Oncolytics Biotech Inc. - Synta Pharmaceuticals Corp. - NanoCarrier Co., Ltd. - Rexahn Pharmaceuticals, Inc. - Colby Pharmaceutical Company - INSYS Therapeutics, Inc. - OncoMed Pharmaceuticals, Inc. - Merrimack Pharmaceuticals, Inc. - Cornerstone Pharmaceuticals, Inc. - Pharma Mar, S.A. - Oncovir, Inc. - Cantex Pharmaceuticals, Inc. - Regulon Inc. - Fountain Biopharma Inc. - Oncozyme Pharma Inc. - AbbVie Inc. - Precision Biologics, Inc. For more information visit http://www.researchandmarkets.com/research/hnpdbv/metastatic
RNN: 0.76 (+0.02), IMMU: 3.76 (+0.12), ONCY: 0.49 (+0.02), OMED: 21.09 (+1.05), PFE: 28.60 (+0.30), INCY: 54.95 (+2.48), LLY: 64.35 (-0.33), GSK: 45.36 (+0.95), MNTA: 11.00 (+0.34), MACK: 9.12 (+0.72), SNTA: 3.02 (+0.09), INSY: 38.38 (-0.31), HALO: 9.26 (+0.32), GILD: 107.18 (+1.09), MRK: 56.63 (+1.12), ABBV: 59.52 (+2.62), NVS: 89.24 (+1.04), CELGZ: 3.57 (+0.03)
Rexahn Pharmaceuticals to Present at 13th Annual BIO Investor Forum
GlobeNewswire - Tue Sep 30, 8:01AM CDT
Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN) a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced that Peter D. Suzdak, PhD, the Company's Chief Executive Officer, will present at the 13 Annual BIO Investor Forum. Hosted by the Biotechnology Industry Organization (BIO), the 13 Annual BIO Investor Forum features leading private and emerging public companies. The presentation will be on Tuesday, October 7 at 10:30 am PDT. The presentation will be webcast live. To access the webcast, please visit http://www.veracast.com/webcasts/bio/investor...151112.cfm. The meeting will take place October 7-8, 2014 at the Palace Hotel in San Francisco, California.
RNN: 0.76 (+0.02)
Rexahn Pharmaceuticals (RNN) Jumps: Stock Gains 10.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 26, 8:25AM CDT
Rexahn Pharmaceuticals (RNN) was a big mover last session, as the company saw its shares rise over 10% on the day.
RNN: 0.76 (+0.02), HSKA: 12.50 (+0.50), CBM: 18.10 (+0.31), GILD: 107.18 (+1.09)
Hot Stock: Rexahn Pharmaceuticals, Shares Gain 8.7% (RNN)
Comtex SmarTrend(R) - Thu Sep 25, 10:07AM CDT
Rexahn Pharmaceuticals (AMEX:RNN) is one of today's best performing penny stocks, up 8.7% to $0.83 on 4.1x average daily volume. Thus far today, Rexahn Pharmaceuticals has traded 4.0 million shares, vs. average volume of 974,000 shares per day. The stock has outperformed the Dow (8.7% to the Dow's -1.1%) and outperformed the S&P 500 (8.7% to the S&P's -1.2%) during today's trading.
RNN: 0.76 (+0.02)
Market Movers - Biotech Stocks - Hemispherx Biopharma, Aegerion Pharma, Cytori Therapeutics, Alnylam Pharma, and Rexahn Pharma
PR Newswire - Thu Sep 25, 8:00AM CDT
The US markets on Wednesday, September 24, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 17,210.06, up 0.90% and the NASDAQ Composite closed at 4,555.22, up 1.03%. The S&P 500 finished the session 0.78% higher at 1,998.30. During the trading session, nine out of ten sectors finished on a higher note The S&P 500 Health Care Sector Index ended the day at 755.42, up 1.68%, with the index gaining 7.83% in the previous three months. Investor-Edge has initiated coverage on the following equities: Hemispherx Biopharma Inc. (NYSE MKT: HEB), Aegerion Pharmaceuticals Inc. (NASDAQ: AEGR), Cytori Therapeutics Inc. (NASDAQ: CYTX), Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY), and Rexahn Pharmaceuticals Inc. (NYSE MKT: RNN). Free research on these five companies can be accessed at:
RNN: 0.76 (+0.02), ALNY: 91.81 (+3.05), CYTX: 0.53 (+0.07), HEB: 0.30 (unch), AEGR: 33.24 (+1.84)
Rexahn Receives FDA Orphan Drug Designation for RX-3117 in Treatment of Pancreatic Cancer
GlobeNewswire - Wed Sep 24, 3:30PM CDT
Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its drug RX-3117 for the treatment of patients with pancreatic cancer. RX-3117 is a next generation, cancer-specific nucleoside analog. Rexahn is currently enrolling patients in a Phase Ib clinical trial in cancer patients and expects to complete this trial in the first quarter of 2015.
RNN: 0.76 (+0.02)
Rexahn Pharmaceuticals to Present at the 14th Annual Biotech in Europe Investor Forum for Global Partnering and Investment in Basel, Switzerland
GlobeNewswire - Tue Sep 23, 9:39AM CDT
Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced that Vikas Sharma, Ph.D., the Company's Director of Business Development, will present at the 14 Annual Biotech in Europe Investor Forum for Global Partnering and Investment in Basel, Switzerland on Tuesday, September 30, 2014 at 10:00 AM (Central European Time). Dr. Sharma will also serve on an expert panel titled "Platform Technologies & Novel Therapeutics" at 4:00 PM (Central European Time). The conference shall be held at Congress Center Basel, Switzerland.
RNN: 0.76 (+0.02)
Stock to Watch: Rexahn Pharmaceuticals Up 7.7% (RNN)
Comtex SmarTrend(R) - Wed Sep 17, 11:37AM CDT
Rexahn Pharmaceuticals (AMEX:RNN) is one of today's best performing penny stocks, up 7.7% to $0.81 on 1.4x average daily volume. Thus far today, Rexahn Pharmaceuticals has traded 1.2 million shares, vs. average volume of 845,000 shares per day. The stock has outperformed the Dow (7.7% to the Dow's 0.0%) and outperformed the S&P 500 (7.7% to the S&P's -0.1%) during today's trading.
RNN: 0.76 (+0.02)
Rexahn Pharmaceuticals to Present at the BioPharm America(TM) 2014 in Boston, Massachusetts, USA
Business Wire - Tue Sep 16, 8:00AM CDT
Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced that Vikas Sharma, PhD, Director of Business Development, will present at the BioPharm America(TM) 2014 conference in Boston, Massachusetts, USA. The presentation will be on Tuesday, September 23rd at 3:00 PM EDT. The conference is being held September 22-24, 2014, at Boston Marriott Copley Place, Boston, Massachusetts, USA.
RNN: 0.76 (+0.02)
Rexahn Pharmaceuticals (RNN) Jumps: Stock Rises 9.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 8:39AM CDT
Rexahn Pharmaceuticals, Inc. (RNN) was a big mover last session, as its shares rose almost 10% on the day.
CBPO: 54.68 (+0.01), RNN: 0.76 (+0.02), CBM: 18.10 (+0.31), GILD: 107.18 (+1.09)
Rexahn Pharmaceuticals to Present at the 16th Annual Rodman & Renshaw Global Investment Conference on September 9, 2014
Business Wire - Thu Sep 04, 8:00AM CDT
Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced that Peter D. Suzdak, PhD, the Company's Chief Executive Officer, will present at the 16th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co, LLC. The presentation will be on Tuesday, September 9th at 12:05 PM EDT. The presentation will be webcast live. To access the webcast, please visit http://wsw.com/webcast/rrshq24/rnn. The conference is being held September 8-10, 2014, at The Palace Hotel in New York City.
RNN: 0.76 (+0.02)
Rexahn Receives a Notice of Allowance from the U.S. Patent and Trademark Office for a Novel Targeted Cancer Drug Delivery Platform
Business Wire - Wed Sep 03, 8:00AM CDT
Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced it has received a notice of allowance from the United States Patent and Trademark Office for a new delivery technology titled, "Polymeric Systems for the Delivery of Anticancer Drugs". The patent covers CPMA, a new polymer drug delivery platform technology developed by Rexahn.
RNN: 0.76 (+0.02)
Market Movers - Biotech Stocks -- Progenics Pharma, Rexahn Pharma, ImmunoGen, Hemispherx Biopharma, and Incyte
PR Newswire - Thu Aug 21, 8:20AM CDT
On Wednesday, August 20, 2014, the NASDAQ Composite ended at 4,526.48, down 0.02%, the Dow Jones Industrial Average finished the day 0.35% higher at 16,979.13, and the S&P 500 closed at 1,986.51, up 0.25%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 726.51, up 0.01%, and the index has advanced 2.23% in the last one month. Investor-Edge has initiated coverage on the following equities: Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), Rexahn Pharmaceuticals Inc. (NYSE MKT: RNN), ImmunoGen Inc. (NASDAQ: IMGN), Hemispherx Biopharma Inc. (NYSE MKT: HEB), and Incyte Corporation (NASDAQ: INCY). Free research on these five companies can be accessed at:
PGNX: 4.61 (+0.05), RNN: 0.76 (+0.02), HEB: 0.30 (unch), INCY: 54.95 (+2.48), IMGN: 9.22 (+0.22)
Rexahn Pharmaceuticals Reports Second Quarter 2014 Financial Results and Pipeline Update
Business Wire - Thu Aug 14, 8:00AM CDT
Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, is providing an overview of its three clinical development programs and financial results for the quarter ended June 30, 2014.
RNN: 0.76 (+0.02)
Rexahn Pharmaceuticals Provides Update on Phase I Supinoxin Trial in Cancer Patients with Solid Tumors
Business Wire - Fri Jul 18, 8:00AM CDT
Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced an update in its Phase I multi-center dose-escalation study to evaluate the safety, tolerability, dose-limiting toxicities and maximum tolerated dose (MTD) of Supinoxin(TM) (RX-5902) in cancer patients with solid tumors.
RNN: 0.76 (+0.02)
Stock to Watch: Rexahn Pharmaceuticals Down 5.2% (RNN)
Comtex SmarTrend(R) - Tue Jul 15, 10:38AM CDT
Rexahn Pharmaceuticals (AMEX:RNN) is one of today's worst performing penny stocks, down 5.2% to $0.76 on 1.1x average daily volume. Thus far today, Rexahn Pharmaceuticals has traded 1.4 million shares, vs. average volume of 1.3 million shares per day. The stock has underperformed the Dow (-5.1% to the Dow's -0.0%) and underperformed the S&P 500 (-5.1% to the S&P's -0.2%) during today's trading.
RNN: 0.76 (+0.02)
What Falling Estimates & Price Mean for Rexahn Pharmaceuticals (RNN) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 16, 7:45AM CDT
Rexahn Pharmaceuticals one such stock considered to drop as it has witnessed a significant price decline and has also seen negative earnings.
RNN: 0.76 (+0.02), GILD: 107.18 (+1.09), ANIP: 28.40 (+0.47), ILMN: 185.84 (+1.02)
Rexahn Pharmaceuticals to Present Data on RX-3117 and RX-21101 at the 2014 American Association for Clinical Research Annual Meeting
Business Wire - Wed Apr 02, 8:00AM CDT
--RX-21101, a nano-polymer targeted form of docetaxel, demonstrates increased efficacy and reduced toxicity
RNN: 0.76 (+0.02)
Metastatic Pancreatic Cancer - Pipeline Review, H2 2014
M2 - Wed Oct 08, 4:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hnpdbv/metastatic) has announced the addition of the "Metastatic Pancreatic Cancer - Pipeline Review, H2 2014" report to their offering. This, Metastatic Pancreatic Cancer - Pipeline Review, H2 2014', provides an overview of the Metastatic Pancreatic Cancer's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Metastatic Pancreatic Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Pancreatic Cancer and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned: - F. Hoffmann-La Roche - AstraZeneca - Eli Lilly and Company - GlaxoSmithKline - Gilead Sciences - Merck & Co - FibroGen - Novartis AG - Pfizer Inc. - Silence Therapeutics plc - Celgene Corporation - Bayer AG - Incyte Corporation - Halozyme Therapeutics, Inc. - Momenta Pharmaceuticals, Inc. - Immunomedics, Inc. - Oncolytics Biotech Inc. - Synta Pharmaceuticals Corp. - NanoCarrier Co., Ltd. - Rexahn Pharmaceuticals, Inc. - Colby Pharmaceutical Company - INSYS Therapeutics, Inc. - OncoMed Pharmaceuticals, Inc. - Merrimack Pharmaceuticals, Inc. - Cornerstone Pharmaceuticals, Inc. - Pharma Mar, S.A. - Oncovir, Inc. - Cantex Pharmaceuticals, Inc. - Regulon Inc. - Fountain Biopharma Inc. - Oncozyme Pharma Inc. - AbbVie Inc. - Precision Biologics, Inc. For more information visit http://www.researchandmarkets.com/research/hnpdbv/metastatic
RNN: 0.76 (+0.02), IMMU: 3.76 (+0.12), ONCY: 0.49 (+0.02), OMED: 21.09 (+1.05), PFE: 28.60 (+0.30), INCY: 54.95 (+2.48), LLY: 64.35 (-0.33), GSK: 45.36 (+0.95), MNTA: 11.00 (+0.34), MACK: 9.12 (+0.72), SNTA: 3.02 (+0.09), INSY: 38.38 (-0.31), HALO: 9.26 (+0.32), GILD: 107.18 (+1.09), MRK: 56.63 (+1.12), ABBV: 59.52 (+2.62), NVS: 89.24 (+1.04), CELGZ: 3.57 (+0.03)
Rexahn Pharmaceuticals to Present at 13th Annual BIO Investor Forum
GlobeNewswire - Tue Sep 30, 8:01AM CDT
Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN) a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced that Peter D. Suzdak, PhD, the Company's Chief Executive Officer, will present at the 13 Annual BIO Investor Forum. Hosted by the Biotechnology Industry Organization (BIO), the 13 Annual BIO Investor Forum features leading private and emerging public companies. The presentation will be on Tuesday, October 7 at 10:30 am PDT. The presentation will be webcast live. To access the webcast, please visit http://www.veracast.com/webcasts/bio/investor...151112.cfm. The meeting will take place October 7-8, 2014 at the Palace Hotel in San Francisco, California.
RNN: 0.76 (+0.02)
Rexahn Pharmaceuticals (RNN) Jumps: Stock Gains 10.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 26, 8:25AM CDT
Rexahn Pharmaceuticals (RNN) was a big mover last session, as the company saw its shares rise over 10% on the day.
RNN: 0.76 (+0.02), HSKA: 12.50 (+0.50), CBM: 18.10 (+0.31), GILD: 107.18 (+1.09)
Hot Stock: Rexahn Pharmaceuticals, Shares Gain 8.7% (RNN)
Comtex SmarTrend(R) - Thu Sep 25, 10:07AM CDT
Rexahn Pharmaceuticals (AMEX:RNN) is one of today's best performing penny stocks, up 8.7% to $0.83 on 4.1x average daily volume. Thus far today, Rexahn Pharmaceuticals has traded 4.0 million shares, vs. average volume of 974,000 shares per day. The stock has outperformed the Dow (8.7% to the Dow's -1.1%) and outperformed the S&P 500 (8.7% to the S&P's -1.2%) during today's trading.
RNN: 0.76 (+0.02)
Market Movers - Biotech Stocks - Hemispherx Biopharma, Aegerion Pharma, Cytori Therapeutics, Alnylam Pharma, and Rexahn Pharma
PR Newswire - Thu Sep 25, 8:00AM CDT
The US markets on Wednesday, September 24, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 17,210.06, up 0.90% and the NASDAQ Composite closed at 4,555.22, up 1.03%. The S&P 500 finished the session 0.78% higher at 1,998.30. During the trading session, nine out of ten sectors finished on a higher note The S&P 500 Health Care Sector Index ended the day at 755.42, up 1.68%, with the index gaining 7.83% in the previous three months. Investor-Edge has initiated coverage on the following equities: Hemispherx Biopharma Inc. (NYSE MKT: HEB), Aegerion Pharmaceuticals Inc. (NASDAQ: AEGR), Cytori Therapeutics Inc. (NASDAQ: CYTX), Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY), and Rexahn Pharmaceuticals Inc. (NYSE MKT: RNN). Free research on these five companies can be accessed at:
RNN: 0.76 (+0.02), ALNY: 91.81 (+3.05), CYTX: 0.53 (+0.07), HEB: 0.30 (unch), AEGR: 33.24 (+1.84)
Rexahn Receives FDA Orphan Drug Designation for RX-3117 in Treatment of Pancreatic Cancer
GlobeNewswire - Wed Sep 24, 3:30PM CDT
Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its drug RX-3117 for the treatment of patients with pancreatic cancer. RX-3117 is a next generation, cancer-specific nucleoside analog. Rexahn is currently enrolling patients in a Phase Ib clinical trial in cancer patients and expects to complete this trial in the first quarter of 2015.
RNN: 0.76 (+0.02)
Rexahn Pharmaceuticals to Present at the 14th Annual Biotech in Europe Investor Forum for Global Partnering and Investment in Basel, Switzerland
GlobeNewswire - Tue Sep 23, 9:39AM CDT
Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced that Vikas Sharma, Ph.D., the Company's Director of Business Development, will present at the 14 Annual Biotech in Europe Investor Forum for Global Partnering and Investment in Basel, Switzerland on Tuesday, September 30, 2014 at 10:00 AM (Central European Time). Dr. Sharma will also serve on an expert panel titled "Platform Technologies & Novel Therapeutics" at 4:00 PM (Central European Time). The conference shall be held at Congress Center Basel, Switzerland.
RNN: 0.76 (+0.02)
Stock to Watch: Rexahn Pharmaceuticals Up 7.7% (RNN)
Comtex SmarTrend(R) - Wed Sep 17, 11:37AM CDT
Rexahn Pharmaceuticals (AMEX:RNN) is one of today's best performing penny stocks, up 7.7% to $0.81 on 1.4x average daily volume. Thus far today, Rexahn Pharmaceuticals has traded 1.2 million shares, vs. average volume of 845,000 shares per day. The stock has outperformed the Dow (7.7% to the Dow's 0.0%) and outperformed the S&P 500 (7.7% to the S&P's -0.1%) during today's trading.
RNN: 0.76 (+0.02)
Rexahn Pharmaceuticals to Present at the BioPharm America(TM) 2014 in Boston, Massachusetts, USA
Business Wire - Tue Sep 16, 8:00AM CDT
Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced that Vikas Sharma, PhD, Director of Business Development, will present at the BioPharm America(TM) 2014 conference in Boston, Massachusetts, USA. The presentation will be on Tuesday, September 23rd at 3:00 PM EDT. The conference is being held September 22-24, 2014, at Boston Marriott Copley Place, Boston, Massachusetts, USA.
RNN: 0.76 (+0.02)
Rexahn Pharmaceuticals (RNN) Jumps: Stock Rises 9.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 8:39AM CDT
Rexahn Pharmaceuticals, Inc. (RNN) was a big mover last session, as its shares rose almost 10% on the day.
CBPO: 54.68 (+0.01), RNN: 0.76 (+0.02), CBM: 18.10 (+0.31), GILD: 107.18 (+1.09)
Rexahn Pharmaceuticals to Present at the 16th Annual Rodman & Renshaw Global Investment Conference on September 9, 2014
Business Wire - Thu Sep 04, 8:00AM CDT
Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced that Peter D. Suzdak, PhD, the Company's Chief Executive Officer, will present at the 16th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co, LLC. The presentation will be on Tuesday, September 9th at 12:05 PM EDT. The presentation will be webcast live. To access the webcast, please visit http://wsw.com/webcast/rrshq24/rnn. The conference is being held September 8-10, 2014, at The Palace Hotel in New York City.
RNN: 0.76 (+0.02)
Rexahn Receives a Notice of Allowance from the U.S. Patent and Trademark Office for a Novel Targeted Cancer Drug Delivery Platform
Business Wire - Wed Sep 03, 8:00AM CDT
Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced it has received a notice of allowance from the United States Patent and Trademark Office for a new delivery technology titled, "Polymeric Systems for the Delivery of Anticancer Drugs". The patent covers CPMA, a new polymer drug delivery platform technology developed by Rexahn.
RNN: 0.76 (+0.02)
Market Movers - Biotech Stocks -- Progenics Pharma, Rexahn Pharma, ImmunoGen, Hemispherx Biopharma, and Incyte
PR Newswire - Thu Aug 21, 8:20AM CDT
On Wednesday, August 20, 2014, the NASDAQ Composite ended at 4,526.48, down 0.02%, the Dow Jones Industrial Average finished the day 0.35% higher at 16,979.13, and the S&P 500 closed at 1,986.51, up 0.25%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 726.51, up 0.01%, and the index has advanced 2.23% in the last one month. Investor-Edge has initiated coverage on the following equities: Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), Rexahn Pharmaceuticals Inc. (NYSE MKT: RNN), ImmunoGen Inc. (NASDAQ: IMGN), Hemispherx Biopharma Inc. (NYSE MKT: HEB), and Incyte Corporation (NASDAQ: INCY). Free research on these five companies can be accessed at:
PGNX: 4.61 (+0.05), RNN: 0.76 (+0.02), HEB: 0.30 (unch), INCY: 54.95 (+2.48), IMGN: 9.22 (+0.22)
Rexahn Pharmaceuticals Reports Second Quarter 2014 Financial Results and Pipeline Update
Business Wire - Thu Aug 14, 8:00AM CDT
Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, is providing an overview of its three clinical development programs and financial results for the quarter ended June 30, 2014.
RNN: 0.76 (+0.02)
Rexahn Pharmaceuticals Provides Update on Phase I Supinoxin Trial in Cancer Patients with Solid Tumors
Business Wire - Fri Jul 18, 8:00AM CDT
Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced an update in its Phase I multi-center dose-escalation study to evaluate the safety, tolerability, dose-limiting toxicities and maximum tolerated dose (MTD) of Supinoxin(TM) (RX-5902) in cancer patients with solid tumors.
RNN: 0.76 (+0.02)
Stock to Watch: Rexahn Pharmaceuticals Down 5.2% (RNN)
Comtex SmarTrend(R) - Tue Jul 15, 10:38AM CDT
Rexahn Pharmaceuticals (AMEX:RNN) is one of today's worst performing penny stocks, down 5.2% to $0.76 on 1.1x average daily volume. Thus far today, Rexahn Pharmaceuticals has traded 1.4 million shares, vs. average volume of 1.3 million shares per day. The stock has underperformed the Dow (-5.1% to the Dow's -0.0%) and underperformed the S&P 500 (-5.1% to the S&P's -0.2%) during today's trading.
RNN: 0.76 (+0.02)
What Falling Estimates & Price Mean for Rexahn Pharmaceuticals (RNN) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 16, 7:45AM CDT
Rexahn Pharmaceuticals one such stock considered to drop as it has witnessed a significant price decline and has also seen negative earnings.
RNN: 0.76 (+0.02), GILD: 107.18 (+1.09), ANIP: 28.40 (+0.47), ILMN: 185.84 (+1.02)
Rexahn Pharmaceuticals to Present Data on RX-3117 and RX-21101 at the 2014 American Association for Clinical Research Annual Meeting
Business Wire - Wed Apr 02, 8:00AM CDT
--RX-21101, a nano-polymer targeted form of docetaxel, demonstrates increased efficacy and reduced toxicity
RNN: 0.76 (+0.02)
